Few stocks in any sector have had the kind of thriving 2013 that NPS Pharmaceuticals (NASDAQ: NPSP) has enjoyed. This biotech stock's up more than 200% year-to-date after receiving approval from the Food and Drug Administration late last year for Gattex, its orphan drug treatment for the rare condition small bowel syndrome, or SBS. Gattex has gotten off to a good start in the first six months of the year, opening up a small but solid patient base as NPS looks to get this rising star going.
It's just the start for Gattex: NPS is hoping the drug can catch on abroad as well, and even conservative peak sales estimates show that this drug has plenty of room to run. But considering this stock's astronomical rise in 2013, have investors who overlooked this stock through most of 2013 missed their chance at big gains?
Fortunately, NPS Pharmaceuticals has plenty of momentum going forward-momentum that could carry shares even higher in the future. In the video below, Fool contributor Dan Carroll tells you what to look for out of NPS in coming quarters -- and how this stock's on pace to keep rising higher over the long term.